What is the clinical evidence from this study?

Study design: Case Report. Population: Anti-Ku myositis with progressive inflammatory myocarditis (n=1). Intervention: Anti-Ku myositis. Primary outcome: Cardiac function and survival.

What does this research mean for the field?

Anti-Ku myositis can present with aggressive, treatment-refractory inflammatory myocarditis that precedes overt muscle symptoms, necessitating early autoimmune testing in cases of unexplained cardiomyopathy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.

September 2, 2026European Heart Journal - Case ReportsOpen Access

Anti-Ku Myositis Presenting with Progressive Inflammatory myocarditis: Diagnostic Pitfalls in a Fatal Case: Case Report

View Full Paper

Ask AI

Bookmark

Key result

Anti-Ku myositis linked to fatal inflammatory myocarditis with LVEF declining to 12% despite aggressive immunosuppression.

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis

Design

Case_report

Follow-up

8 months

Authors

AEAhmed ELBekiey MZMohamed Wahib Zhlawi JTJie Tong

Discussion

Member takes

Overview

Highlights potential fatality in anti-Ku myocarditis despite immunosuppression; leaves open role of early antibody screening.

Key Points

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.
Clinical, diagnostic, and therapeutic evaluation of a 60-year-old male presenting with progressive heart failure and subsequent proximal myopathy.
Diagnostic procedures included serial echocardiography, coronary angiography, cardiac MRI, deltoid muscle biopsy, and myositis-specific antibody immunoblotting.
Left-ventricular ejection fraction progressively declined from an initial 49% to 12%, complicated by high-grade atrioventricular block requiring dual-chamber pacing.
Immunoblot confirmed high-titre anti-Ku antibodies and deltoid biopsy showed inflammatory myopathy, alongside serum creatine kinase of 2,680 IU/L and troponin I of 928 ng/L.
Despite combination immunosuppression with corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin, cardiac failure proved refractory, resulting in death at eight months.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis and heart failure, followed for 8 months until death.

Exposure

High-dose corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin

Outcome

Clinical course and survival

Anti-Ku myositis can present with aggressive cardiac involvement and may be refractory to conventional immunosuppression once advanced cardiomyopathy is established.

Cite This Study

ELBekiey et al. (2026) conducted a case report in Anti-Ku myositis with progressive inflammatory myocarditis (n=1). Anti-Ku myositis was evaluated on Cardiac function and survival. Anti-Ku myositis in a 60-year-old man led to fatal progressive inflammatory myocarditis, with left ventricular ejection fraction declining from 49% to 12% despite aggressive immunosuppression.

synapsesocial.com/papers/6a97e2eac562ede874ec7441 https://doi.org/10.1093/ehjcr/ytag625

View Full Paper

Ask AI

Bookmark

September 2, 2026European Heart Journal - Case ReportsOpen Access

Anti-Ku Myositis Presenting with Progressive Inflammatory myocarditis: Diagnostic Pitfalls in a Fatal Case: Case Report

View Full Paper

Ask AI

Bookmark

Key result

Anti-Ku myositis linked to fatal inflammatory myocarditis with LVEF declining to 12% despite aggressive immunosuppression.

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis

Design

Case_report

Follow-up

8 months

Authors

AEAhmed ELBekiey MZMohamed Wahib Zhlawi JTJie Tong

Discussion

Member takes

Overview

Highlights potential fatality in anti-Ku myocarditis despite immunosuppression; leaves open role of early antibody screening.

Key Points

To describe a fatal presentation of anti-Ku overlap myositis masquerading as isolated cardiac disease and identify clinical pitfalls in diagnosis and management.
Clinical, diagnostic, and therapeutic evaluation of a 60-year-old male presenting with progressive heart failure and subsequent proximal myopathy.
Diagnostic procedures included serial echocardiography, coronary angiography, cardiac MRI, deltoid muscle biopsy, and myositis-specific antibody immunoblotting.
Left-ventricular ejection fraction progressively declined from an initial 49% to 12%, complicated by high-grade atrioventricular block requiring dual-chamber pacing.
Immunoblot confirmed high-titre anti-Ku antibodies and deltoid biopsy showed inflammatory myopathy, alongside serum creatine kinase of 2,680 IU/L and troponin I of 928 ng/L.
Despite combination immunosuppression with corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin, cardiac failure proved refractory, resulting in death at eight months.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 60-year-old man with anti-Ku myositis presenting with progressive inflammatory myocarditis and heart failure, followed for 8 months until death.

Exposure

High-dose corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin

Outcome

Clinical course and survival

Anti-Ku myositis can present with aggressive cardiac involvement and may be refractory to conventional immunosuppression once advanced cardiomyopathy is established.

Cite This Study

synapsesocial.com/papers/6a97e2eac562ede874ec7441 https://doi.org/10.1093/ehjcr/ytag625

View Full Paper

Ask AI

Bookmark